An Open-Label Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of DC50292A Tablet in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors
Latest Information Update: 30 Jul 2025
At a glance
- Drugs DC 50292A (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Heronova Pharmaceuticals
Most Recent Events
- 30 Jul 2025 New trial record